The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 19, 2019

Filed:

Oct. 25, 2013
Applicant:

Memorial Sloan-kettering Cancer Center, New York, NY (US);

Inventors:

Minna D. Balbas, New York, NY (US);

Charles L. Sawyers, New York, NY (US);

Philip Watson, New York, NY (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/53 (2006.01); A61K 31/4439 (2006.01); C12Q 1/6886 (2018.01); A61K 31/4166 (2006.01); A61K 49/00 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C12N 15/113 (2010.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4439 (2013.01); A61K 31/4166 (2013.01); A61K 49/0008 (2013.01); C07K 14/70567 (2013.01); C07K 16/2857 (2013.01); C12N 15/1138 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5011 (2013.01); C07K 2317/76 (2013.01); C12N 2310/14 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/723 (2013.01);
Abstract

The present invention encompasses the recognition that an F876L mutation of the androgen receptor (AR) gene confers resistance to the antiandrogens enzalutamide (MDV3100) and ARN-509 and is associated with incidence and/or risk of castration resistant prostate cancer (CRPC). The present invention also provides other AR polypeptide sequences associated with increased incidence and/or risk of CRPC. The present invention also provides screening methods for identification and/or characterization of novel AR polypeptide sequences associated with increased incidence and/or risk of CRPC via exposure to antiandrogens and for identification and/or characterization of agents to treat and/or reduce risk of CRPC by virtue of their effect on AR transcriptional activation.


Find Patent Forward Citations

Loading…